Arcus Biosciences (RCUS) Interest Coverage Ratio (2017 - 2026)
Arcus Biosciences' (RCUS) quarterly Interest Coverage Ratio came in at 44.67 in Q1 2026, up 26.78% year-on-year from 35.23 in Q1 2025, and down 25.82% quarter-over-quarter from 35.5 in Q3 2025.
Arcus Biosciences (RCUS) Interest Coverage Ratio (2017 - 2026) Analysis & Trends
Arcus Biosciences' Interest Coverage Ratio history runs 10 years deep, the most recent figure standing at 44.67 for Q1 2026.
- On a quarterly basis, Interest Coverage Ratio rose 26.78% year-over-year to 44.67 in Q1 2026; TTM through Mar 2026 was 49.75, a 31.54% increase from a year earlier, with the FY2025 full-year figure at 0.94, up 10.29% from the prior year.
- Interest Coverage Ratio retreated to 44.67 in Q1 2026 per RCUS's latest filing, from 35.5 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 0.49 in Q4 2022 and bottomed at 106.0 in Q2 2024.
- The 5-year median for Interest Coverage Ratio is 21.5 (2023), against an average of 35.2.
- Across the five-year window, Interest Coverage Ratio plunged 410.84% in 2024 and jumped 92.45% in 2025, its largest moves.
- Year by year, Interest Coverage Ratio stood at 0.49 in 2022, then sank by 5305.41% to 26.67 in 2023, then tumbled by 93.12% to 51.5 in 2024, then surged by 31.07% to 35.5 in 2025, then declined by 25.82% to 44.67 in 2026.
- Per Business Quant, the three latest RCUS Interest Coverage Ratio figures stand at 44.67 (Q1 2026), 35.5 (Q3 2025), and 8.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -157.58 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 7.60 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -0.38 |
| 10 | Arcus Biosciences | 3.57 Bn | 2.75 Bn | - | -44.67 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.67 |
| Sep 30, 2025 | -35.50 |
| Jun 30, 2025 | -8.00 |
| Mar 31, 2025 | -61.00 |
| Dec 31, 2024 | -51.50 |
| Sep 30, 2024 | -105.00 |
| Jun 30, 2024 | -106.00 |
| Mar 31, 2024 | -16.00 |
| Sep 30, 2023 | -26.67 |
| Jun 30, 2023 | -20.75 |
| Mar 31, 2023 | -21.50 |
| Dec 31, 2022 | -0.49 |
| Sep 30, 2022 | -7.12 |
| Jun 30, 2022 | -9.51 |
| Mar 31, 2022 | -14.25 |
| Dec 31, 2021 | 281.02 |
| Sep 30, 2021 | -4.91 |
| Jun 30, 2021 | -12.48 |
| Dec 31, 2020 | -25.11 |
| Dec 31, 2019 | -7.26 |